- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00945815
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
S0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination With Cytarabine and Clofarabine for Patients With Relapsed or Refractory Ph- Negative Precursor B-Cell Acute Lymphoblastic Leukemia
RATIONALE: Monoclonal antibodies, such as epratuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving epratuzumab together with cytarabine and clofarabine may kill more cancer cells.
PURPOSE: This phase II trial is studying the side effects and how well giving epratuzumab together with cytarabine and clofarabine works in treating patients with relapsed or refractory acute lymphoblastic leukemia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- To test whether the complete remission (CR) rate (CR and incomplete CR) in adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia is sufficiently high after treatment with cytarabine, clofarabine, and epratuzumab to warrant further investigation.
- To estimate the frequency and severity of toxicities associated with the dosing schedule of cytarabine, clofarabine, and epratuzumab used in this study.
- To investigate, preliminarily, the effect of laboratory correlates (minimal post-treatment residual disease) and cytogenetic factors on prognosis in this patient population. (Not reported here due to limited MRD data)
OUTLINE: This is a multicenter study.
Patients receive cytarabine IV over 2 hours on days 1-5, clofarabine IV over 1 hour on days 2-6, and epratuzumab IV over at least 1 hour on days 7, 14, 21, and 28 in the absence of disease progression or unacceptable toxicity*.
NOTE: * Prophylactic intrathecal methotrexate is required for patients < 22 years of age, and is recommended (but not required) for patients ≥ 22 years of age.
Blood samples, bone marrow samples, and/or tumor tissue samples may be collected for further laboratory analysis.
Patients are followed up every 3 months for 2 years, then annually for 3 years (until 5 years after registration).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
-
California
-
Duarte, California, United States, 91010-3000
- City of Hope Comprehensive Cancer Center
-
Los Angeles, California, United States, 90089-9181
- USC/Norris Comprehensive Cancer Center and Hospital
-
Sacramento, California, United States, 95817
- University of California Davis Cancer Center
-
Stanford, California, United States, 94305-5824
- Stanford Cancer Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Cancer Center at UC Health Sciences Center
-
Grand Junction, Colorado, United States, 81502
- St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
-
-
Florida
-
Tampa, Florida, United States, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
-
Indiana
-
Beech Grove, Indiana, United States, 46107
- St. Francis Hospital and Health Centers - Beech Grove Campus
-
Richmond, Indiana, United States, 47374
- Reid Hospital & Health Care Services
-
-
Louisiana
-
Alexandria, Louisiana, United States, 71315-3198
- Tulane Cancer Center Office of Clinical Research
-
Baton Rouge, Louisiana, United States, 70809
- Hematology-Oncology Clinic
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0942
- University of Michigan Comprehensive Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Cancer Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Saint Louis University Cancer Center
-
-
Montana
-
Billings, Montana, United States, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, United States, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, United States, 59107-7000
- Billings Clinic - Downtown
-
Billings, Montana, United States, 59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman, Montana, United States, 59715
- Bozeman Deaconess Cancer Center
-
Great Falls, Montana, United States, 59405
- Great Falls Clinic - Main Facility
-
Great Falls, Montana, United States, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
Helena, Montana, United States, 59601
- St. Peter's Hospital
-
Kalispell, Montana, United States, 59901
- Kalispell Regional Medical Center
-
Kalispell, Montana, United States, 59901
- Glacier Oncology, PLLC
-
Missoula, Montana, United States, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, United States, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
New York
-
Rochester, New York, United States, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28233-3549
- Presbyterian Cancer Center at Presbyterian Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Charles M. Barrett Cancer Center at University Hospital
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer Center
-
Dayton, Ohio, United States, 45405
- Grandview Hospital
-
Dayton, Ohio, United States, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, United States, 45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton, Ohio, United States, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, United States, 45420
- CCOP - Dayton
-
Findlay, Ohio, United States, 45840
- Blanchard Valley Medical Associates
-
Franklin, Ohio, United States, 45005-1066
- Middletown Regional Hospital
-
Greenville, Ohio, United States, 45331
- Wayne Hospital
-
Kettering, Ohio, United States, 45429
- Charles F. Kettering Memorial Hospital
-
Troy, Ohio, United States, 45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Xenia, Ohio, United States, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
Greenville, South Carolina, United States, 29615
- CCOP - Greenville
-
Greenville, South Carolina, United States, 29605
- Cancer Centers of the Carolinas - Faris Road
-
Greenville, South Carolina, United States, 29605
- Cancer Centers of the Carolinas - Grove Commons
-
Greer, South Carolina, United States, 29650
- Cancer Centers of the Carolinas - Greer Medical Oncology
-
Seneca, South Carolina, United States, 29672
- Cancer Centers of the Carolinas - Seneca
-
Spartanburg, South Carolina, United States, 29307
- Cancer Centers of the Carolinas - Spartanburg
-
-
Texas
-
Houston, Texas, United States, 77030
- Ben Taub General Hospital
-
Houston, Texas, United States, 77030
- Veterans Affairs Medical Center - Houston
-
Houston, Texas, United States, 77030
- Baylor University Medical Center - Houston
-
Houston, Texas, United States, 77030
- St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital
-
-
Utah
-
American Fork, Utah, United States, 84003
- American Fork Hospital
-
Cedar City, Utah, United States, 84720
- Sandra L. Maxwell Cancer Center
-
Logan, Utah, United States, 84321
- Logan Regional Hospital
-
Murray, Utah, United States, 84157
- Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
-
Ogden, Utah, United States, 84403
- Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
-
Provo, Utah, United States, 84604
- Utah Valley Regional Medical Center - Provo
-
Saint George, Utah, United States, 84770
- Dixie Regional Medical Center - East Campus
-
Salt Lake City, Utah, United States, 84143
- LDS Hospital
-
-
Washington
-
Anacortes, Washington, United States, 98221
- Island Hospital Cancer Care Center at Island Hospital
-
Bellingham, Washington, United States, 98225
- St. Joseph Cancer Center
-
Bremerton, Washington, United States, 98310
- Olympic Hematology and Oncology
-
Burien, Washington, United States, 98166
- Highline Medical Center Cancer Center
-
Issaquah, Washington, United States, 98029
- Swedish Medical Center - Issaquah Campus
-
Kennewick, Washington, United States, 99336
- Columbia Basin Hematology
-
Mount Vernon, Washington, United States, 98274
- Skagit Valley Hospital Cancer Care Center
-
Poulsbo, Washington, United States, 98370
- Harrison Poulsbo Hematology and Onocology
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, United States, 98104
- Harborview Medical Center
-
Seattle, Washington, United States, 98112
- Group Health Central Hospital
-
Seattle, Washington, United States, 98122-4307
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
-
Seattle, Washington, United States, 98122
- Polyclinic First Hill
-
Seattle, Washington, United States, 98195
- University Cancer Center at University of Washington Medical Center
-
Sedro-Woolley, Washington, United States, 98284
- North Puget Oncology at United General Hospital
-
Spokane, Washington, United States, 99202
- Cancer Care Northwest - Spokane South
-
Spokane, Washington, United States, 99218
- Evergreen Hematology and Oncology, PS
-
Wenatchee, Washington, United States, 98801-2028
- Wenatchee Valley Medical Center
-
-
Wyoming
-
Sheridan, Wyoming, United States, 82801
- Welch Cancer Center at Sheridan Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Morphologically confirmed precursor B-cell acute lymphoblastic leukemia (ALL) (non T-cell)
Must have evidence of disease in bone marrow or peripheral blood
- Immunophenotyping of the blood or marrow lymphoblasts must be performed to determine lineage (B cell, T cell, or mixed B/T cell)
- Must have ≥ 5% lymphoblasts present in the blood or bone marrow
At least 20% of marrow and/or peripheral blood lymphoblasts must be CD22+ by flow cytometry
- Co-expression of myeloid antigens (CD13 and CD33) allowed
- Patients with only extramedullary disease in the absence of bone marrow or blood involvement are not eligible
Philadelphia (Ph) chromosome-negative disease
- Patients with unknown Ph status by cytogenetics or FISH and unknown BCR/ABL status by PCR are eligible for study registration, but must be removed from study therapy if found to be Ph+ or BCR/ABL+ after study registration
Refractory to a standard induction regimen that included vincristine and prednisone or high-dose cytarabine or mitoxantrone OR relapsed after successful prior induction therapy
- Any number of prior induction therapies or any number of remissions achieved are allowed
- No M0 acute myeloid leukemia, mixed lineage leukemia, or L3 (Burkitt) leukemia
No active CNS involvement by clinical evaluation
- Patients with a documented history of CNS involvement of ALL or with clinical signs or symptoms consistent with CNS involvement of ALL must undergo a lumbar puncture that is negative for CNS involvement of ALL
- Patients < 22 years of age must be willing to receive prophylactic intrathecal chemotherapy
- Must be registered on SWOG-9007 "Cytogenetic Studies in Leukemia Patients" (closed as of 07/01/2010)
PATIENT CHARACTERISTICS:
- Zubrod performance status 0-2
- Serum creatinine ≤ 1.0 mg/dL OR glomerular filtration rate > 60 mL/min
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 times ULN
- Bilirubin ≤ 1.5 times ULN
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment
HIV-positive patients are eligible (at the discretion of the investigator) provided the following criteria are met:
- No history of AIDS-defining conditions
- CD4 cell count > 350/mm³
- If on antiretroviral agents, must not include zidovudine or stavudine
- Willing to receive prophylaxis for pneumocystis jirovecii pneumonia during study therapy (regardless of CD4 cell count) until the CD4 cell count is > 200/mm³ after completion of study treatment
- Prior malignancy (other than ALL) allowed provided it is in remission and there are no plans to treat the malignancy at the time of study registration
- No uncontrolled systemic fungal, bacterial, viral, or other infection, defined as exhibiting ongoing signs or symptoms related to the infection with no improvement despite appropriate antibiotics or other treatment
- No neuropathy (cranial, motor or sensory) ≥ grade 2
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Any number of prior therapies allowed
More than 90 days since prior allogeneic bone marrow transplant (BMT)
- No concurrent immunosuppression therapy for the treatment of graft-vs-host disease (GVHD)
- No acute GVHD ≥ grade 2, moderate or severe limited chronic GVHD, or extensive chronic GVHD of any severity
Prior autologous BMT allowed
- No concurrent immunosuppression therapy for the treatment of GVHD
More than 14 days since prior chemotherapy, investigational agents, or major surgery and recovered
- Maintenance therapy with steroids, vincristine, and/or anti-metabolite agents, including but not limited to, mercaptopurine, thioguanine, and methotrexate allowed
- Concurrent hydroxyurea to reduce WBC to a reasonable level (as deemed by the treating physician) allowed
- No prior clofarabine or epratuzumab
- No other concurrent cytotoxic therapy or investigational therapy
- No concurrent alternative medications (e.g., herbal or botanical medications for anticancer purposes)
- Concurrent participation on SWOG-S9910 "Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary" allowed (closed as of 07/01/2010)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: treatment
AraC 1 g/m2/d IV Days 1-5 clofarabine 40 mg/m2/d IV Days 2-6 epratuzumab 360 mg/m2/d IV Days 7, 14, 21, 28 acetaminophen 650 mg/d PO Days 7, 14, 21, 28 diphenhydramine 50 mg/d IV Days 7, 14, 21, 28 IT methotrexate 12 mg IT at least 1 wk apart during induction All give 1 cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Remission
Time Frame: After induction therapy was completed (1 or 2 months)
|
Complete remission (CR) is defined as: <5% marrow aspirate blasts.
Blasts can be >=5% if the blasts are found to be myeloid and there is no evidence of lymphoblasts by flow cytometry or immunostaining.
Neutrophils >= 1000/mcl; platelets >100,000/mcl; and no blasts in the peripheral blood.
C1 Extramedullary disease status as defined in the protocol.
Complete remission with incomplete platelet recovery (CRi) is same as CR but platelet count may be <=100,000/mcl and/or ANC may be <1,000/mcl.
|
After induction therapy was completed (1 or 2 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Grade 3 Through 5 Treatment-Related Adverse Events
Time Frame: Up to 5 years
|
Only adverse events that are possibly, probably or definitely related to study drug are reported.
Any CTCAE 4.0 event of Grade 3 (severe), Grade 4 (life threatening), or Grade 5 (fatal) which were deemed to be related to protocol treatment are included.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Epratuzumab
- Clofarabine
- Cytarabine
Other Study ID Numbers
- S0910 (OTHER: SWOG)
- U10CA032102 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States